Perspective of first line immune therapy of non-small-cell lung cancer
In this MEDtalk Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, gives his perspective on treatment of non-small cell Lung cancer with immune therapy as first line treatment. He also gives his answer on how oncologists can choose wisely and how he would explain the survival benefit in the cemiplimab arm according to EMPOWER Lung 1 study.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.